STOCK TITAN

Jasper Therapeutics: Armistice reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. (JSPR) reported that Armistice Capital, LLC and its managing member, Steven Boyd, each may be deemed to beneficially own 123,102 shares of Voting Common Stock, or 9.99% of the class, as of September 30, 2026. Armistice Capital has shared voting and dispositive power over the shares under its investment management agreement with Armistice Capital Master Fund Ltd., which directly holds them.

Beneficial ownership 123,102 shares Reported by Armistice Capital, LLC and Steven Boyd as of September 30, 2026.
Percent of class 9.99% Jasper Therapeutics Voting Common Stock reported as beneficially owned as of September 30, 2026.
beneficial ownership regulatory
"may be deemed to beneficially own the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"Shared voting power: 123,102"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Investment Management Agreement financial
"pursuant to an Investment Management Agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Joint Filing Statement Pursuant to Rule 13d-1(k) regulatory
"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many JSPR shares did Armistice Capital and Steven Boyd report owning?

Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 123,102 shares, representing 9.99% of Jasper Therapeutics’ Voting Common Stock as of September 30, 2026.

Who directly holds the reported JSPR shares and receives dividends or sale proceeds?

Armistice Capital Master Fund Ltd. directly holds the shares and has the right to receive dividends or proceeds from their sale. Armistice Capital, LLC exercises shared voting and investment power over the shares under an investment management agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





471871301

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/16/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Keep reading